Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Research & Development (2019 - 2025)

Historic Research & Development for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $19.5 million.

  • Keros Therapeutics' Research & Development fell 6034.74% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.4 million, marking a year-over-year decrease of 491.2%. This contributed to the annual value of $173.6 million for FY2024, which is 2836.87% up from last year.
  • As of Q3 2025, Keros Therapeutics' Research & Development stood at $19.5 million, which was down 6034.74% from $43.5 million recorded in Q2 2025.
  • Keros Therapeutics' Research & Development's 5-year high stood at $49.2 million during Q3 2024, with a 5-year trough of $10.0 million in Q2 2021.
  • In the last 5 years, Keros Therapeutics' Research & Development had a median value of $31.1 million in 2023 and averaged $29.6 million.
  • As far as peak fluctuations go, Keros Therapeutics' Research & Development surged by 13320.65% in 2022, and later crashed by 6034.74% in 2025.
  • Keros Therapeutics' Research & Development (Quarter) stood at $18.8 million in 2021, then surged by 32.04% to $24.9 million in 2022, then surged by 50.77% to $37.5 million in 2023, then grew by 21.71% to $45.6 million in 2024, then crashed by 57.22% to $19.5 million in 2025.
  • Its last three reported values are $19.5 million in Q3 2025, $43.5 million for Q2 2025, and $48.7 million during Q1 2025.